Incidence of Extrapyramidal Symptoms Was Similar Between INVEGA HAFYERA™ and INVEGA TRINZA® (paliperidone palmitate)

Chart depicting incidence of extrapyramidal symptoms from the double-blind phase

*Use of anti-EPS medication during the double-blind phase.

Percentage of patients with Simpson-Angus Scale Global Score >0.3 (Global Score defined as the total sum of items score divided by the number of items).

Percentage of patients with Barnes Akathisia Rating Scale Global Clinical Rating Score ≥2.

§Percentage of patients with a score ≥3 on any of the first 7 items or a score ≥2 on 2 or more of any of the first 7 items of the Abnormal Involuntary Movement Scale.

Note: Percentages are calculated based on the number of patients in the DB Safety analysis set per treatment group.

EPS=extrapyramidal symptoms.

DB=double-blind phase.

REFERENCE: 1. INVEGA HAFYERA™ [Prescribing Information]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; August 2021.